What Is Compounded Tirzepatide?
Compounded tirzepatide is a version of the weight-loss and diabetes drug tirzepatide that is mixed by a compounding pharmacy instead of being made by the drug's FDA-approved manufacturer. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they are sold.
Tirzepatide itself is FDA-approved under two brand names: Zepbound for chronic weight management and Mounjaro for type 2 diabetes. Compounders may make versions of a drug on the FDA's shortage list if they meet conditions in federal law. Tirzepatide injection was in shortage from 2022 until the FDA declared the shortage resolved in October 2024, a decision it confirmed in December 2024.
Compounded Tirzepatide at a Glance
| What it is | A pharmacy-made version of tirzepatide. Not FDA-approved. |
|---|---|
| FDA-approved versions | Zepbound (weight management, and moderate to severe obstructive sleep apnea in adults with obesity) and Mounjaro (type 2 diabetes) |
| How tirzepatide works | Activates receptors for two gut hormones, GLP-1 and GIP, to reduce appetite and food intake |
| How it's given | Brand-name tirzepatide is a once-weekly injection under the skin. Some compounded semaglutide and tirzepatide products are sublingual or dissolving tablets. |
| Common side effects | Nausea, diarrhea, vomiting, constipation and stomach pain |
| Expert guidance | The American Diabetes Association and leading obesity medicine groups recommend against compounded versions |
What Is Compounded Tirzepatide Used For?
Compounded tirzepatide is used by some patients as an unapproved option for weight loss. Zepbound is for adults with obesity (a BMI of 30 or higher) or overweight (a BMI of 27 or higher) with at least one weight-related condition. It is used with a reduced-calorie diet and more physical activity.
The FDA says a compounded drug may be appropriate only when a patient's medical need can't be met by an FDA-approved drug, such as an allergy to a dye in the approved product, or when the approved drug isn't commercially available.
How Does Compounded Tirzepatide Work?
Compounded tirzepatide is meant to work like brand-name tirzepatide, but no FDA review confirms what a compounded product contains. Tirzepatide:
- Activates GLP-1 and GIP receptors to reduce appetite and food intake
- Helps the pancreas release insulin when blood sugar is high
- Slows the emptying of the stomach
Poor compounding can cause contamination or too much or too little active ingredient. The FDA is also aware of fraudulent compounded tirzepatide labeled with pharmacies that don't exist. A 2026 study of 33 compounded semaglutide and tirzepatide products found that 48% added extras such as vitamin B12, glycine or ondansetron, with little justification for adding nutrients.
How Is Compounded Tirzepatide Taken?
Compounded tirzepatide may be an injection or a tablet. Brand-name tirzepatide is injected under the skin once a week. Zepbound starts at 2.5 mg weekly for 4 weeks, then rises in 2.5 mg steps at least 4 weeks apart, up to a maximum of 15 mg weekly.
Compounded products may come in multi-dose vials for self-injection. The FDA advises patients to:
- Throw the vial away within 28 days of first use, even if medication remains
- Use a new, sterile needle and syringe for every dose
- Not use a product that arrives warm or poorly refrigerated
- Ask the prescriber or compounder how to measure your dose
The FDA has received adverse event reports tied to compounded tirzepatide prescribed at larger doses, more often or with faster increases than the approved label.
Side Effects and Risks of Compounded Tirzepatide
Compounded tirzepatide can cause tirzepatide's usual side effects, plus risks from quality and dosing problems.
Common Side Effects
Common side effects include nausea, diarrhea, vomiting, constipation, stomach discomfort and pain, injection site reactions, fatigue, allergic reactions, burping, hair loss and acid reflux.
Serious Warnings
Zepbound's FDA label carries a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. Whether it does so in humans is unknown. The label also warns of severe digestive reactions, pancreatitis, gallbladder disease, kidney injury from fluid loss, low blood sugar with insulin or medicines that boost insulin release, such as sulfonylureas, suicidal thoughts, and aspiration during anesthesia.
Risks Specific to Compounding
As of May 31, 2026, the FDA had received more than 730 adverse event reports for compounded tirzepatide. State-licensed pharmacies that aren't outsourcing facilities don't have to report them, so the true number is likely higher. A study of FDA adverse event reports from 2018 to 2024 found higher reporting odds of hospitalization, contamination and preparation errors for compounded GLP-1 drugs than non-compounded ones. The study wasn't designed to show cause and effect.
Who Shouldn't Take Compounded Tirzepatide?
Compounded tirzepatide should not be used by anyone who shouldn't take tirzepatide, including people who:
- Have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Have had a serious allergic reaction to tirzepatide
- Are pregnant
- Have severe gastroparesis
- Already use another tirzepatide product or a GLP-1 receptor agonist
Compounded Tirzepatide vs. Zepbound and Mounjaro
Compounded tirzepatide shares an ingredient name with Zepbound and Mounjaro, but only the brand-name products are FDA-approved and tested in clinical trials.
| Compounded tirzepatide | Zepbound and Mounjaro | |
|---|---|---|
| FDA-approved | No | Yes |
| Oversight | Mainly state boards of pharmacy. FDA-registered outsourcing facilities follow manufacturing (CGMP) rules. | FDA-approved manufacturer |
| Clinical evidence | Efficacy and safety largely unknown | In a 72-week Zepbound trial, adults without diabetes on the 15 mg dose lost an average of 18% of body weight compared with placebo |
Compounded Tirzepatide Evaluation at GENEVA
At GENEVA Primary Care & Med Spa in Alpharetta, GA, a provider asked about compounded tirzepatide evaluates your weight, health history and medications, then recommends treatment at GENEVA or a referral to a specialist.
Learn more about medical weight loss and primary care in Alpharetta. GENEVA serves patients from Alpharetta, Johns Creek, Milton, Roswell and Cumming.
Related Terms
- Tirzepatide injections
- Zepbound
- Mounjaro
- Dual GIP/GLP-1 agonist
- Tirzepatide titration schedule
- Compounded semaglutide
Compounded Tirzepatide FAQs
Is compounded tirzepatide FDA-approved?
No, compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. The only FDA-approved tirzepatide products are Zepbound, for weight management and obstructive sleep apnea, and Mounjaro, for type 2 diabetes. Compounded drugs are not generics either, because generics must be FDA-approved and shown to be equivalent to the brand-name drug. If you're offered compounded tirzepatide, ask why an FDA-approved product won't meet your needs.
Is compounded tirzepatide the same as Zepbound?
No, compounded tirzepatide is not the same as Zepbound, even though both are labeled tirzepatide. Zepbound comes from its approved manufacturer and was tested in clinical trials, while the efficacy and safety of compounded products are largely unknown. A 2026 study of 33 compounded semaglutide and tirzepatide products found that 48% added ingredients such as vitamin B12, glycine or ondansetron, and some were sublingual or dissolving tablets. The FDA calls a seller's claim that a compounded drug is the same as an FDA-approved drug a red flag.
Is compounded tirzepatide still legal?
Compounded tirzepatide is legal only in limited situations now that the FDA has declared the tirzepatide shortage resolved, most recently in December 2024. State-licensed pharmacies generally can't regularly compound copies of a commercially available drug unless the prescriber documents a significant difference for an individual patient. The FDA has said that, for now, it doesn't intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month. The FDA has also warned companies that illegally sold tirzepatide falsely labeled "for research purposes."
Is compounded tirzepatide safe?
Compounded tirzepatide carries more uncertainty than FDA-approved tirzepatide, and the American Diabetes Association does not recommend non-FDA-approved compounded products. Besides tirzepatide's usual side effects, such as nausea, vomiting and diarrhea, compounded versions can have contamination, the wrong dose or fraudulent labels. As of May 31, 2026, the FDA had received more than 730 adverse event reports for compounded tirzepatide, likely an undercount. Get any prescription filled only at a state-licensed pharmacy, and report problems to the FDA's MedWatch program.
How much weight can you lose on tirzepatide?
The effect of compounded tirzepatide on weight is largely unknown, but FDA-approved tirzepatide has been tested in large trials. In a 72-week trial, adults without diabetes taking 15 mg of Zepbound weekly lost an average of 18% of their body weight compared with placebo. If you haven't lost at least 5% after 12 to 16 weeks at your highest tolerated dose, another medication may be considered. In a separate trial, people switched to placebo after 36 weeks saw their weight rise by an average of 14% over the next 52 weeks, and experts recommend a long-term approach to treatment.
Can a primary care provider evaluate you for tirzepatide?
Yes, a primary care provider can evaluate whether a weight-loss medication such as tirzepatide fits your health needs. At GENEVA in Alpharetta, a provider reviews your weight, health history and current medications, then recommends treatment at GENEVA or a referral to a specialist. Zepbound is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Tell your provider about any family history of medullary thyroid cancer, pregnancy or plans to become pregnant, and any planned surgery.